Ovid Therapeutics (OVID) Non Operating Income (2016 - 2020)
Ovid Therapeutics' (OVID) quarterly Non Operating Income came in at $590491.0 in Q2 2020, up 122.83% YoY from $264999.0 in Q3 2019, and up 123.42% on a QoQ basis from $264296.0 in Q1 2020.
Ovid Therapeutics (OVID) Non Operating Income (2016 - 2020) Analysis & Trends
Ovid Therapeutics (OVID) has 5 years of Non Operating Income data on file, last reported at $590491.0 in Q2 2020.
- Quarterly Non Operating Income rose 122.83% year-over-year to $590491.0 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $1.3 million (up 35.48% YoY) and the FY2019 annual result came in at $948224.0, changed 0.4% from the prior year.
- Non Operating Income rose to $590491.0 in Q2 2020, from $264296.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $590491.0 in Q2 2020 to a low of $23000.0 in Q1 2017.
- A 5-year average of $170951.4 and a median of $172500.0 in 2018 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2018 — Non Operating Income surged 973.91% — and 2019, when it sank 38.79%.
- Tracing OVID's Non Operating Income over 5 years: stood at $27000.0 in 2016, then surged by 225.93% to $88000.0 in 2017, then soared by 145.45% to $216000.0 in 2018, then surged by 38.43% to $299000.0 in 2019, then soared by 97.49% to $590491.0 in 2020.
- The last three Non Operating Income figures came in at $590491.0 (Q2 2020), $264296.0 (Q1 2020), and $299000.0 (Q4 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 590,491.00 |
| Mar 31, 2020 | 264,296.00 |
| Dec 31, 2019 | 299,000.00 |
| Sep 30, 2019 | 131,000.00 |
| Jun 30, 2019 | 264,999.00 |
| Mar 31, 2019 | 253,340.00 |
| Dec 31, 2018 | 216,000.00 |
| Sep 30, 2018 | 214,000.00 |
| Jun 30, 2018 | 275,000.00 |
| Mar 31, 2018 | 247,000.00 |
| Dec 31, 2017 | 88,000.00 |
| Sep 30, 2017 | 51,000.00 |
| Jun 30, 2017 | 40,000.00 |
| Mar 31, 2017 | 23,000.00 |
| Dec 31, 2016 | 27,000.00 |
| Sep 30, 2016 | 30,000.00 |
| Jun 30, 2016 | 31,000.00 |
| Mar 31, 2016 | 32,000.00 |